Production (Stage)
Cytophage Technologies Ltd.
CYTO.V
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.89% | 6.92% | |||
| Depreciation & Amortization | 39.32% | -2.15% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.80% | 5.39% | |||
| Operating Income | 5.80% | -5.39% | |||
| Income Before Tax | 8.92% | -11.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 8.92% | -11.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.92% | -11.13% | |||
| EBIT | 5.80% | -5.39% | |||
| EBITDA | 13.07% | -6.22% | |||
| EPS Basic | 9.09% | -11.49% | |||
| Normalized Basic EPS | 3.09% | -4.30% | |||
| EPS Diluted | 9.09% | -11.49% | |||
| Normalized Diluted EPS | 3.09% | -4.30% | |||
| Average Basic Shares Outstanding | -0.02% | 0.20% | |||
| Average Diluted Shares Outstanding | -0.02% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||